A few things gleaned from today's conference call announcement:
Bronchiectasis was first diagnosed (and named) in 1819. Since then no drug (pharmaceutical) treatments have been available.
Company expects 250,000 patients in US to get the drug upon launch. There are over 500,000 diagnosed with bronchiectasis. There are approx. 17,000 pulmonologists in US.
There are 2 drug strengths, 10mg and 25 mg tablets. Pulmonologists will decide on what dose each patient receives and which patients receive it. The guidelines are 2 exacerbations a year, but the decision to prescribe is up to each pulmonologist.
"Time to fill" is approximately 1-month's time. Insmed is presently negotiating with payers, dealing with labelling etc.
60% of patients receiving drug are on Medicare.
Formulary vs exception. Brinsupri will be an exception process for now. One of the reasons for a Q3 launch is that many patients are near or at their OOP maximums, so theoretically Brinsupri may cost them zero dollars.
Competitive landscape - none exists for at least 2-3 years.

Oddly, no one asked about side effects!